Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Hematology

Living with an MPN: Symptoms, Surveillance, and Survivorship

At a Glance

Living with a myeloproliferative neoplasm (MPN) often involves managing daily symptoms like fatigue and brain fog, even when blood counts are normal. Tracking your symptoms with the MPN-10 tool and maintaining a consistent surveillance schedule is key to preserving your quality of life.

Living with a myeloproliferative neoplasm (MPN) is often a marathon, not a sprint. While your medical team may focus heavily on your “numbers” (blood counts), your daily experience is defined by your symptom burden—the physical and emotional toll the disease takes on your body [1][2].

Understanding Constitutional Symptoms

MPN symptoms are often called constitutional symptoms. They are systemic, meaning they affect your whole body, and they often do not correlate perfectly with your blood counts. You can have “perfect” lab results and still feel profoundly unwell [3][4].

Common symptoms include:

  • Fatigue: The most frequent symptom, often described as an overwhelming exhaustion that sleep doesn’t fix [1].
  • Brain Fog: Cognitive impairment and difficulty concentrating are among the most frustrating daily symptoms patients deal with [1].
  • Pruritus (Itching): Often triggered by warm water (like a shower), this is a hallmark especially of Polycythemia Vera [1].
  • Early Satiety: Feeling full after eating only a small amount of food, often caused by an enlarged spleen pressing on the stomach [5].
  • Night Sweats and Bone Pain: Signs of the inflammation caused by the overactive signaling pathways in your marrow [1][5].

Measuring What Matters: The MPN-10

To help your doctor understand your experience, researchers developed the MPN-SAF TSS (also called the MPN-10) [6]. This is a simple 0–10 scale for ten key symptoms. NCCN guidelines now recommend using this tool at every visit to ensure your treatment is actually improving your quality of life, not just your labs [5][7]. If your score is high, it may be a signal that your disease is progressing or that your current medication needs to be adjusted [6][8].

A Framework for Surveillance

Consistency is the key to managing a chronic MPN. While every patient is different, a standard surveillance schedule typically includes:

  • Blood Work (CBC): Every 1 to 4 months for stable patients; more frequent if you are changing medications or undergoing phlebotomy [9].
  • Physical Exam: At every visit, your doctor should “palpate” (feel) your abdomen to check for an enlarged spleen [5].
  • Bone Marrow Biopsy: While a biopsy is absolutely essential for your initial diagnosis, it is not done routinely for ongoing surveillance. It is usually only repeated if there is a significant change in your blood counts, a sudden increase in symptoms, or concern that the disease is progressing [10][11].
  • Secondary Screenings: Because MPN patients have a higher risk of second cancers—especially non-melanoma skin cancers linked to the use of hydroxyurea—annual skin checks with a dermatologist are mandatory [12][13].

The Psychological Weight: Survivorship

Living with “cancer” that is also a “chronic disease” creates a unique psychological burden. Many patients experience scanxiety—intense stress before lab results are released—and more than 25% of MPN patients report clinical depression or anxiety [14].

Advocating for Yourself: You are the expert on how you feel. If your doctor says “your numbers look great” but you can barely get through the day due to fatigue, it is important to voice that. Management of an MPN is about more than just preventing a blood clot; it is about ensuring you can live your life with as much energy and clarity as possible [4][15].

Back to Home Page

Common questions in this guide

What is the MPN-10 score used for?
The MPN-10 is a simple scoring system that tracks ten common myeloproliferative neoplasm symptoms on a scale from zero to ten. Doctors use it to measure your symptom burden and ensure your treatment is actually improving your daily quality of life, rather than just treating your blood counts.
Why do I feel so tired even when my MPN blood counts are normal?
Myeloproliferative neoplasms cause constitutional symptoms, which are systemic issues driven by inflammation from your bone marrow. Because of this, you can experience severe fatigue, brain fog, and bone pain even if your laboratory results look perfectly normal.
How often do I need a bone marrow biopsy for an MPN?
While a bone marrow biopsy is essential for your initial diagnosis, it is not typically part of routine surveillance. Your doctor will usually only order another biopsy if there is a sudden change in your blood counts, significantly worsening symptoms, or concern that the disease is progressing.
Why do MPN patients need regular skin checks with a dermatologist?
People with an MPN have a higher risk of developing secondary cancers, particularly non-melanoma skin cancers. This risk is increased by the use of certain medications like hydroxyurea, making regular screenings with a dermatologist an essential part of your care.
Why do I feel full after eating only a small amount of food?
Feeling full quickly when eating is a symptom known as early satiety. In MPN patients, this is frequently caused by an enlarged spleen that physically presses against the stomach, limiting how much food you can comfortably eat.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can we go over my most recent MPN-10 score together and discuss if my treatment needs adjustment based on my symptoms?
  2. 2.How often should I be getting blood work, and what specific 'triggers' would make us decide to repeat a bone marrow biopsy?
  3. 3.Are my current symptoms—like fatigue, brain fog, or itching—within the 'expected' range, or should we be more aggressive in managing them?
  4. 4.Do you have a nurse practitioner or social worker on the team who specializes in the psychological impact of living with a chronic blood cancer?
  5. 5.Since my risk for skin cancer and other second malignancies is higher, what is the recommended schedule for my dermatologic exams?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms.

    Huberty J, Eckert R, Gowin K, et al.

    Haematologica 2017; (102(10)):e384-e388 doi:10.3324/haematol.2017.168583.

    PMID: 28596279
  2. 2

    Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study.

    Christensen SF, Svingel LS, Kjaersgaard A, et al.

    European journal of haematology 2022; (109(5)):526-541 doi:10.1111/ejh.13841.

    PMID: 35900040
  3. 3

    Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.

    Scherber RM, Kosiorek HE, Senyak Z, et al.

    Cancer 2016; (122(3)):477-85 doi:10.1002/cncr.29753.

    PMID: 26670597
  4. 4

    Polycythemia Vera (PV): Update on Emerging Treatment Options.

    Benevolo G, Vassallo F, Urbino I, Giai V

    Therapeutics and clinical risk management 2021; (17()):209-221 doi:10.2147/TCRM.S213020.

    PMID: 33758507
  5. 5

    Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis

    Ümit EG, Baysal M, Kırkızlar HO, Demir AM

    Turkish journal of haematology : official journal of Turkish Society of Haematology 2024; (41(3)):175-181 doi:10.4274/tjh.galenos.2024.2024.0011.

    PMID: 38801033
  6. 6

    From symptom scales to regulatory endpoints: the evolution and clinical impact of patient-reported outcome measures in myeloproliferative neoplasms.

    Chen M, Zheng C, Xie J, et al.

    Clinical and experimental medicine 2025; (25(1)):330 doi:10.1007/s10238-025-01830-9.

    PMID: 41138008
  7. 7

    Approach to MPN Symptom Assessment.

    Geyer H, Mesa RA

    Current hematologic malignancy reports 2017; (12(5)):381-388 doi:10.1007/s11899-017-0399-5.

    PMID: 28942516
  8. 8

    MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients.

    ElNahass YH, Mahmoud HK, Mattar MM, et al.

    Leukemia & lymphoma 2018; (59(4)):844-854 doi:10.1080/10428194.2017.1365852.

    PMID: 28828906
  9. 9

    Contemporary approach to essential thrombocythemia and polycythemia vera.

    Aruch D, Mascarenhas J

    Current opinion in hematology 2016; (23(2)):150-60 doi:10.1097/MOH.0000000000000216.

    PMID: 26717193
  10. 10

    A Case Report on Hepatic Extramedullary Hematopoiesis as the Manifestation of Progression to Secondary Myelofibrosis in a Patient with Essential Thrombocytopenia.

    McArthur KI, Papayanis PN, Nguyen MHK, et al.

    Hematology reports 2022; (14(4)):286-289 doi:10.3390/hematolrep14040040.

    PMID: 36278517
  11. 11

    Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.

    Bartels S, Vogtmann J, Schipper E, et al.

    European journal of haematology 2021; (106(4)):520-528 doi:10.1111/ejh.13579.

    PMID: 33460496
  12. 12

    Risk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis.

    Mishra R, Bagga A, Sharafeldin N, et al.

    JCO oncology practice 2025; OP2500431 doi:10.1200/OP-25-00431.

    PMID: 41397215
  13. 13

    Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms.

    Stefanou MI, Richter H, Härtig F, et al.

    European journal of neurology 2019; (26(6)):903-e64 doi:10.1111/ene.13907.

    PMID: 30629793
  14. 14

    Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.

    Padrnos L, Scherber R, Geyer H, et al.

    Cancer medicine 2020; (9(22)):8301-8309 doi:10.1002/cam4.3380.

    PMID: 32976697
  15. 15

    Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF TSS or MPN-10) Questionnaire.

    Găman MA, Scherber RM, Ursuleac I, et al.

    Journal of clinical medicine 2024; (13(11)) doi:10.3390/jcm13113284.

    PMID: 38892995

This page provides general educational information about myeloproliferative neoplasm (MPN) symptom management and surveillance. It does not replace professional medical advice. Always discuss your specific symptoms and monitoring schedule with your hematologist or oncologist.

Get notified when new evidence is published on Myeloproliferative neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.